vs
Side-by-side financial comparison of ACADIA PHARMACEUTICALS INC (ACAD) and Perella Weinberg Partners (PWP). Click either name above to swap in a different company.
ACADIA PHARMACEUTICALS INC is the larger business by last-quarter revenue ($284.0M vs $219.2M, roughly 1.3× Perella Weinberg Partners). ACADIA PHARMACEUTICALS INC runs the higher net margin — 96.3% vs 6.3%, a 90.0% gap on every dollar of revenue. On growth, ACADIA PHARMACEUTICALS INC posted the faster year-over-year revenue change (9.4% vs -2.9%). Over the past eight quarters, Perella Weinberg Partners's revenue compounded faster (46.5% CAGR vs 17.5%).
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.
PJT Partners, Inc. is a global advisory-focused investment bank, founded in October 2015 as part of The Blackstone Group's spin-off of its financial and strategic advisory services businesses.
ACAD vs PWP — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $284.0M | $219.2M |
| Net Profit | $273.6M | $13.8M |
| Gross Margin | 90.8% | — |
| Operating Margin | 6.1% | 8.5% |
| Net Margin | 96.3% | 6.3% |
| Revenue YoY | 9.4% | -2.9% |
| Net Profit YoY | 90.3% | — |
| EPS (diluted) | $1.61 | $0.11 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $284.0M | $219.2M | ||
| Q3 25 | $278.6M | $164.6M | ||
| Q2 25 | $264.6M | $155.3M | ||
| Q1 25 | $244.3M | $211.8M | ||
| Q4 24 | $259.6M | $225.7M | ||
| Q3 24 | $250.4M | $278.2M | ||
| Q2 24 | $242.0M | $272.0M | ||
| Q1 24 | $205.8M | $102.1M |
| Q4 25 | $273.6M | $13.8M | ||
| Q3 25 | $71.8M | $6.0M | ||
| Q2 25 | $26.7M | $2.7M | ||
| Q1 25 | $19.0M | $17.3M | ||
| Q4 24 | $143.7M | — | ||
| Q3 24 | $32.8M | $16.4M | ||
| Q2 24 | $33.4M | $-66.0M | ||
| Q1 24 | $16.6M | $-35.8M |
| Q4 25 | 90.8% | — | ||
| Q3 25 | 92.2% | — | ||
| Q2 25 | 92.2% | — | ||
| Q1 25 | 91.7% | — | ||
| Q4 24 | 91.6% | — | ||
| Q3 24 | 92.5% | — | ||
| Q2 24 | 92.5% | — | ||
| Q1 24 | 88.8% | — |
| Q4 25 | 6.1% | 8.5% | ||
| Q3 25 | 12.8% | 5.4% | ||
| Q2 25 | 12.2% | 5.8% | ||
| Q1 25 | 7.9% | 5.5% | ||
| Q4 24 | 59.1% | — | ||
| Q3 24 | 12.6% | 12.9% | ||
| Q2 24 | 12.6% | -30.2% | ||
| Q1 24 | 7.4% | -52.4% |
| Q4 25 | 96.3% | 6.3% | ||
| Q3 25 | 25.8% | 3.6% | ||
| Q2 25 | 10.1% | 1.8% | ||
| Q1 25 | 7.8% | 8.2% | ||
| Q4 24 | 55.4% | — | ||
| Q3 24 | 13.1% | 5.9% | ||
| Q2 24 | 13.8% | -24.3% | ||
| Q1 24 | 8.0% | -35.1% |
| Q4 25 | $1.61 | $0.11 | ||
| Q3 25 | $0.42 | $0.08 | ||
| Q2 25 | $0.16 | $0.04 | ||
| Q1 25 | $0.11 | $0.24 | ||
| Q4 24 | $0.86 | — | ||
| Q3 24 | $0.20 | $0.24 | ||
| Q2 24 | $0.20 | $-1.21 | ||
| Q1 24 | $0.10 | $-0.91 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $177.7M | $255.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.2B | $-127.4M |
| Total Assets | $1.6B | $797.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $177.7M | $255.9M | ||
| Q3 25 | $258.0M | $185.5M | ||
| Q2 25 | $253.6M | $145.0M | ||
| Q1 25 | $217.7M | $111.2M | ||
| Q4 24 | $319.6M | $407.4M | ||
| Q3 24 | $155.1M | $335.1M | ||
| Q2 24 | $177.1M | $185.3M | ||
| Q1 24 | $204.7M | $156.7M |
| Q4 25 | $1.2B | $-127.4M | ||
| Q3 25 | $917.3M | $-302.4M | ||
| Q2 25 | $822.4M | $-318.4M | ||
| Q1 25 | $765.2M | $-323.1M | ||
| Q4 24 | $732.8M | $-421.4M | ||
| Q3 24 | $577.2M | $-360.8M | ||
| Q2 24 | $516.7M | $-283.0M | ||
| Q1 24 | $464.0M | $161.9M |
| Q4 25 | $1.6B | $797.6M | ||
| Q3 25 | $1.3B | $650.2M | ||
| Q2 25 | $1.2B | $606.7M | ||
| Q1 25 | $1.1B | $570.5M | ||
| Q4 24 | $1.2B | $876.8M | ||
| Q3 24 | $976.9M | $810.9M | ||
| Q2 24 | $914.1M | $645.5M | ||
| Q1 24 | $855.1M | $583.6M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-48.7M | $34.8M |
| Free Cash FlowOCF − Capex | — | $30.5M |
| FCF MarginFCF / Revenue | — | 13.9% |
| Capex IntensityCapex / Revenue | — | 2.0% |
| Cash ConversionOCF / Net Profit | -0.18× | 2.52× |
| TTM Free Cash FlowTrailing 4 quarters | — | $-34.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-48.7M | $34.8M | ||
| Q3 25 | $74.3M | $59.2M | ||
| Q2 25 | $64.0M | $56.1M | ||
| Q1 25 | $20.3M | $-176.5M | ||
| Q4 24 | $40.4M | $223.4M | ||
| Q3 24 | $63.2M | $200.3M | ||
| Q2 24 | $25.0M | $90.0M | ||
| Q1 24 | $29.1M | $-206.3M |
| Q4 25 | — | $30.5M | ||
| Q3 25 | $73.9M | $57.6M | ||
| Q2 25 | — | $55.3M | ||
| Q1 25 | — | $-177.6M | ||
| Q4 24 | — | $207.0M | ||
| Q3 24 | $63.2M | $199.3M | ||
| Q2 24 | — | $83.7M | ||
| Q1 24 | — | $-214.8M |
| Q4 25 | — | 13.9% | ||
| Q3 25 | 26.5% | 35.0% | ||
| Q2 25 | — | 35.6% | ||
| Q1 25 | — | -83.8% | ||
| Q4 24 | — | 91.7% | ||
| Q3 24 | 25.2% | 71.6% | ||
| Q2 24 | — | 30.8% | ||
| Q1 24 | — | -210.3% |
| Q4 25 | — | 2.0% | ||
| Q3 25 | 0.1% | 0.9% | ||
| Q2 25 | — | 0.5% | ||
| Q1 25 | — | 0.5% | ||
| Q4 24 | — | 7.3% | ||
| Q3 24 | 0.0% | 0.4% | ||
| Q2 24 | — | 2.3% | ||
| Q1 24 | — | 8.3% |
| Q4 25 | -0.18× | 2.52× | ||
| Q3 25 | 1.03× | 9.85× | ||
| Q2 25 | 2.40× | 20.50× | ||
| Q1 25 | 1.07× | -10.18× | ||
| Q4 24 | 0.28× | — | ||
| Q3 24 | 1.93× | 12.23× | ||
| Q2 24 | 0.75× | — | ||
| Q1 24 | 1.76× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACAD
| Nuplazid | $174.4M | 61% |
| Daybue | $109.6M | 39% |
PWP
Segment breakdown not available.
